Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
TripleMed logo — Creating minimally invasive solutions for aneurysms, providi...

TripleMed

Creating minimally invasive solutions for aneurysms, providing a seamless blood flow to other arteries for a longer-lasting treatment.

Founded 2011 Series A Total: $2.00M Biotechnology, Health Care

General Information

Company Name TripleMed
Founded Year 2011
Industries Biotechnology, Health Care
Funding Stage Series A
Social

Get notified when TripleMed moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About TripleMed

TripleMed is a biotechnology startup founded in 2011 with a focus on creating minimally invasive solutions for aneurysms. Their slogan emphasizes the goal of providing a seamless blood flow to other arteries for a longer-lasting treatment. The company's description highlights their innovative approach, as they aim to eliminate the need for incisions with their initial product, which not only fills the aneurysm, blocking blood entry, but also maintains a channel for blood flow to surrounding arteries. This offers a superior and enduring answer to aortic aneurysms. In September 2017, TripleMed secured a €2.00M Series A investment from Chemelot Ventures and the Limburg Business Development Fund (LBDF). This investment not only reflects confidence in the startup's potential but also provides them with the necessary resources to further develop their groundbreaking solutions. TripleMed's focus on minimally invasive treatments aligns with the growing demand for advanced healthcare technologies, positioning them at the forefront of innovation in the healthcare industry.

Taxonomy: minimally invasive surgery, aneurysm treatment, vascular health, interventional cardiology, medical innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 2
Investor
•••• •••• 		18 Sep 2017

TripleMed Alternatives & Competitors

TripleMed vs
Artio Medical
Artio Medical

Precision Tools for Rapid and Safe Vascular Occlusion Procedures

Series A
11-50 employees
Biotechnology, Health Care
Compare TripleMed vs Artio Medical
TripleMed vs
Micro Therapeutics
Micro Therapeutics

Innovative solutions for neurovascular and peripheral vascular disease treatment.

Health Care, Health and Wellness
TripleMed vs
Fluid Biomed Inc.
Fluid Biomed Inc. Canada

Developing the next generation of stents to improve patient well-being.

Non Equity Assistance
24 employees
Health Care, Medical Devices

FAQ About TripleMed

Creating minimally invasive solutions for aneurysms, providing a seamless blood flow to other arteries for a longer-lasting treatment.
TripleMed was founded in 2011.
TripleMed operates in the following industries: Biotechnology, Health Care.
TripleMed has completed 1 funding round, raising a total of $2.00M. The latest funding stage is Series A.
Top alternatives and competitors to TripleMed include Artio Medical, Micro Therapeutics, Fluid Biomed Inc., Oxford Endovascular Ltd., LuSeed Vascular. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TripleMed and Artio Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors TripleMed and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy